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ABSTRACT
Parkinson’s disease (PD) is one of the most debilitating
neurodegenerative diseases in the world. PD is typically characterized by its
motor symptoms which commonly include tremors, rigidity, postural instability,
and repetitive or involuntary muscle movements. Some of the most common nonmotor symptoms include cognitive impairment, personality changes, depression,
and anxiety. Depression has shown to be a prominent symptom in individuals
with PD which affects them at any point during disease progression. However, it
has been suggested that depression is more common among individuals with
early-onset PD compared to individuals with later onsets. Our first aim
investigated depression rates among individuals newly diagnosed with young
(< 49 years old), middle (50-69 years old), and late onset Parkinson’s disease
(> 70 years old). Our second aim investigated the neural correlates of depression
among young (YOPD), middle (MOPD), and late onset PD (LOPD) individuals.
The current study utilized data from the Parkinson’s Progression Marker’s
Initiative (PPMI) database. The PPMI is a longitudinal multisite observational
study to measure and identify biomarkers of Parkinson’s disease progression.
The overall sample consisted of 487 newly diagnosed PD patients who
completed a questionnaire of depression at each annual follow-up for a period of
five years (aim 1). A subsample of 133 participants underwent head MRI at
baseline and first annual follow-up to investigate the neural correlates of
depression (aim 2). Multilevel modeling (MLM) examined longitudinal group
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differences in depression severity, and the association between depression and
structural brain markers among age groups. Results for our first aim indicated a
significant group X occasion interaction effect. More specifically, the LOPD group
had higher depression scores overtime than the MOPD group in a model without
medications. However, when medications were added in the model, these effects
were no longer significant. Overall, this sample had an average score of 2.46 in
the GDS-15 form suggesting that individuals were generally non-depressed. For
our second aim, lower neuronal density in the frontal medial cortex was
significantly associated with more depression in the MOPD group. Overall, our
findings show that age of onset is significantly associated with depression
severity between the LOPD and the MOPD groups. Furthermore, the frontal
medial cortex significantly deteriorates over time as depression increases in the
MOPD group.
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CHAPTER ONE
INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative
disorder followed by Alzheimer’s disease (National Institute of Aging [NIA], 2017).
Nearly one million Americans are diagnosed with PD, which is expected to rise to
1.2 million by the year 2030, and more than 10 million people have PD worldwide
(Marras et al., 2018; Parkinson’s Foundation, 2021). The prevalence of PD
exponentially increases as individuals age (Pringsheim et al., 2014).
Interestingly, men are 1.5 times more likely than women to have PD (Parkinson’s
Foundation, 2020). PD typically begins at the age of 60, but symptoms can
manifest earlier, and worsen over time (National Institute of Neurological
Disorders and Stroke [NINDS], 2020). As disease progresses, motor, and
cognitive symptoms exacerbate and could lead to death. There is no cure for PD,
but specific-targeted drug treatments and therapies can be developed to alleviate
the motor and non-motor symptoms.

Etiology
Parkinson’s disease was first described as a neurological movement
disorder by James Parkinson in the 1800s (Weintraub et al., 2008). Early studies
of PD identified this disease as a distinct movement disorder. Movement
dysfunctions in PD are attributed to the loss of dopaminergic neurons in the
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substantia nigra (SN) pars compacta (Williams-Gray & Worth, 2016). Dopamine
(DA) release mediates communication between the substantia nigra, the basal
ganglia, and regions of the frontal cortex which are important for calibration of
movement (Triarhou, 2000-2013). In Parkinson’s disease, both nigral
subpopulations, dorsal and ventral, are affected, but there is much more severe
neuronal loss in the ventral SN region (Gibb & Lees, 1991). Interestingly, early
symptoms of PD do not develop until there is a major reduction of dopamine in
the striatum (Zhai et al., 2018). According to the National Health Service (2019)
symptoms of PD begin appearing when about 80% of the neurons in the
substantia nigra are lost. Additionally, cholinergic loss has been linked to PD
severity, more specifically akinesia or inability to perform voluntary movement
and gait deficits (Bohnen et al., 2013).
Abundant Lewy bodies are also found in PD patients, which are
predominant in areas of neuronal loss such as the substantia nigra and locus
coeruleus (Schultz-Schaeffer, 2010). Lewy bodies are mainly composed of the
alpha-synuclein (SNCA) protein (abnormal protein deposits), and accumulation of
these have been associated with neurotoxicity (Schulz-Schaeffer, 2010;
Parkkinen et al., 2011). These protein deposits cause neurons to work less
efficiently and eventually die. Furthermore, Lewy bodies can be formed in
different brain regions affecting neurochemicals such as dopamine and
norepinephrine which can lead to the motor and non-motor symptoms observed
in PD (National Institute of Aging [NIH], 2017).
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Risk Factors
Age
One of the strongest risk factors of PD is age. PD is a neurological
disorder that rarely affects young adults; it begins in middle or late life. The
development of medicine and treatment over the past decades have allowed
populations to live longer, therefore, also increasing the occurrence of
neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and
other types of dementia. As healthy individuals age, there is significant neuronal
loss observed in multiple brain regions, but with extensive neuronal loss
observed in the substantia nigra (SN) (Reeve et al., 2014). Several factors in the
environment of the SN such as dopamine metabolism and oxidative stress, pacemaking activity, or the handling of calcium in the SN for neuron excitability
(important for maintenance of DA levels within the striatum), iron concentration
changes, and neuromelanin accumulation, influence cell loss as individuals
normally age (as reviewed in Reeve et al., 2014). Therefore, it is believed that
the accumulation of these age-related changes weaken neurons in the substantia
nigra, making it possible for the expression of PD symptoms (Reeve et al., 2014).
Consequently, neurons in the substantia nigra predispose individuals to develop
the motor and non-motor symptoms observed in PD.
Genetics
Genetics is another important risk factor of PD. According to the
Parkinson’s Foundation (2020) about 10% to 15% of PD cases are a cause of
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genetics; however, environment, lifestyle, and other factors play a role in PD
development. Recently discovered autosomal-dominant gene mutations
associated with PD are Gly51Asp, and those found in the SNCA (Lesage et al.,
2013; Kiely et al., 2013). The genes involved in an autosomal-recessive pattern
are PARK7, PINK1, or PRKN (MedlinePlus, 2012). However, sporadic cases or
those that appear with no family history of disorder, are the most common.
Genes can play a major role in future PD cognitive decline and dementia (Morley
et al., 2012).
Environment
Environment also plays a major role in the prevalence of PD. Studies
reviewed by Palin et al., (2015) found an association between hydrocarbon
exposure and the risk of developing PD. Interestingly, 13 review studies indicated
that the risk of PD increases by 32% when individuals are exposed to
hydrocarbon (Palin et al., 2015). Furthermore, other important environmental risk
factors are exposure to pesticides, herbicides, and solvents, but not to fungicides
(Pezzoli & Cereda, 2013; van der Mark et al., 2012). Paraquat (a herbicide), and
rotenone (an insecticide) exposure have been most commonly associated with
the development of PD, as these chemicals have shown to increase oxidative
stress, and disrupt mitochondrial energy production (Mostafalou & Abdollahi,
2013; Dexter & Jenner, 2013). Furthermore, another type of pesticide called
organochlorine (insecticide) has been associated with elevated amounts of
dieldrin and beta-hexachlorocyclohexane, compounds associated with increased
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oxidative stress and inflammation (as reviewed by Kamel, 2013). Other studies
have further supported that exposure to pesticides has been associated with the
development of idiopathic (cause is unknown) PD (Allen & Levy, 2013; Stykel et
al., 2018).
Gender
Gender is also an important risk factor of PD. PD seems to occur 1.5x
more in men than in women (Parkinson’s Foundation, 2020). Some studies
suggest that perhaps the typical “male lifestyle” such as more exposure to
environmental toxins, or head trauma, account for these differences (Wooten et
al., 2004). Regarding the onset of PD, some studies have shown that PD starts
earlier in men with PD starting 2.1 years later in women (Haaxma et al., 2007).
An important risk factor commonly observed in women is anemia (Savica et al.,
2013). Moreover, women display later onset of motor symptoms, and they tend to
be more tremor dominant, as opposed to other motor symptoms such as rigidity
(Haaxma et al., 2007; Solla et al., 2012). Augustine et al. (2015) also found
gender differences in cognitive impairment. Women in this study demonstrated
better SCOPA-COG (Scales for Outcomes in Parkinson’s Disease Cognition; a
self-report measure of cognitive difficulties) and SDMT (Symbol Digit Modalities
test; an objective measure of processing speed) performance than men (Solla et
al., 2012). Moreover, women displayed higher and more severe symptoms of
anxiety and more severe symptoms of depression leading to worse quality of life
(Kovacs et al., 2016).
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Substances
Substances such as alcohol intake, coffee drinking, and smoking have
also been associated with PD. Alcohol intake, specifically beer, has been
inversely associated with PD, meaning that it could prevent or slow down PD
progression (Zhang et al., 2014). Beer contains purine, which may elevate
plasma urate levels, and ultimately cause antioxidants which protect cells from
damage; Therefore, purine has been associated with lower PD risk (Weisskopf et
al., 2007). Coffee and smoking have also been negatively associated with PD.
Interestingly, coffee reduces the risk of having PD by 33% and alcohol intake
reduces it by 10% (Noyce et al., 2012). Of particular interest, a study found that
A2A antagonists, caffeine being one of them, protect against neurodegeneration
of dopaminergic neurons (Kachroo et al., 2010). The intake of vitamin B6 was
also found to be negatively correlated with PD (Shen, 2015). Although these
substances have been associated with risk reduction of PD, findings vary, and
are unclear (Hernan et al., 2002; Costa et al., 2010; Hernan et al., 2003).

Motor Symptoms
Parkinson’s disease is mainly known for its evident motor abnormalities
such as slow movement, tremors, impaired posture/balance, stiffness, speech,
and writing difficulties (American Parkinson’s Disease Association [APDA],
2020). Younger people with PD may only notice one or two of the motor
symptoms before they become worse (APDA, 2020).
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According to the APDA (2020), tremors affect around 80% of individuals
with PD. Tremors in PD are different from other types of tremors as they tend to
appear when a person is at rest– a “resting tremor” (APDA, 2020). Furthermore,
bradykinesia or slowness of movement is another important symptom of PD.
Dystonia, or repetitive or involuntary muscle movements and vocal symptoms are
also present. These are some of the primary motor symptoms observed in
Parkinson’s disease and typically appear during the initial stages (APDA, 2021).

Non-Motor Symptoms
Dysfunctions of the basal ganglia have not only been associated with the
movement abnormalities in PD, but also with non-motor symptoms such as
depression, and cognitive impairment. Some studies using monkey models
suggest that the basal ganglia is organized into three regions: sensorimotor,
associative, and limbic (Parent & Hazrati, 1995). More specifically, the
associative region comprises parts of the putamen, and caudate nucleus, and it
receives projections from several association cortices in the frontal, temporal,
and parietal lobes (Goldman & Nauta, 1977). The sensorimotor region receives
information from cortical fibers from primary motor and somatosensory cortices
(Liles & Updyke, 1985). Lastly, the limbic region receives projections from the
limbic and paralimbic cortices, amygdala, and the hippocampus (Alheid &
Heimer, 1988). These regions project to the subthalamic nucleus, and
pallidosubthalamic, which have been associated with PD symptomatology, and
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have been a target for surgery in PD (Karachi et al., 2005). Thus, these findings
provide further support of the neural bases of the non-motor aspects of PD.
Non-motor symptoms in PD include disturbances in sense of smell, sleep
problems, pain, psychosis, fatigue, weight loss, gastrointestinal issues,
personality changes, cognitive impairment, depression, and anxiety (APDA,
2020). These symptoms are often overlooked since PD is mainly recognized and
diagnosed based on the movement abnormalities, but the non-motor symptoms
are significantly important for a patient's quality of life.
Cognitive impairment (CI) is an important non-motor aspect of PD as it is
associated with significant disability (Watson & Leverenz, 2010). Cognitive
decline is evident in normal aging, but in PD it worsens as disease progresses.
Cognitive impairments commonly involve dysfunction of several domains
including executive functioning such as planning or organizing tasks, learning
and memory, attention, and language (Williams-Gray & Worth, 2016). According
to Litvan et al., (2012) mild cognitive impairment (MCI), a transitional state of
gradual decline in cognitive abilities, predicts the development of PD dementia
(PDD), which occurs in up to 80% of PD patients. Parkinson’s disease dementia
refers to severe decline in thinking and reasoning. More specifically, PDD
involves deficits in recognition memory, visual perception, and more severe
cognitive decline (Pagonabarraga & Kulisevsky, 2012).
Depression is another important non-motor symptom of Parkinson’s
disease. There is research suggesting that depression is more common in
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individuals with PD compared to healthy elderly adults. According to KirschDarrow et al., (2006) around 31% of individuals with PD will experience
depression. Individuals with PD may experience sadness due to family
distancing, losing friendships, or adapting to new changes; however, sadness
greatly differs from depression. Depression is persistent and can last for weeks,
months, even years.
Depression is defined as a mental illness that negatively impacts the way
a person feels, thinks, and behaves (American Psychiatric Association [APA],
2021). It affects individuals in any population, regardless of age, gender, or
ethnicity. According to the World Health Organization (WHO, 2021) more than
264 million people worldwide are affected by depression, and close to 800,000
individuals commit suicide every year. Depression symptoms vary from mild to
severe, and can include difficulty thinking, loss of energy, feeling sad, and feeling
worthless or guilty (APA, 2021). There are many causes of depression including
brain changes, stressful life events, genetic vulnerability, abuse, medical
problems, and medications (Harvard Health Publishing, 2009).
Neurobiological factors such as neuronal reduction or malfunction
contribute to depression. Depression is not only influenced by the levels of these
neurotransmitters in the brain (dopamine, norepinephrine, and serotonin), but
also by nerve cell connections, nerve cell growth, and functioning of neuron
circuitry (Racagni & Brunello, 1999). Reduction of an important neurotransmitter,
serotonin, which is involved in mood, has been associated with depression (Tan
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et al., 2011). Degeneration of the serotonin transmission system, specifically in
the midbrain raphe nuclei, has been prominent in studies using Parkinson’s
disease rat models (Hou et al., 2012). Furthermore, the study by Remy et al.,
(2005) found that depressed PD patients had lower [11C]RTI-32 binding (an in
vivo marker of dopamine and noradrenaline transporter binding) in many regions
of the limbic system, including the anterior cingulate cortex, the thalamus, the
amygdala, and the ventral striatum, but also the locus coeruleus, compared to
non-depressed patients. These findings further support the idea that progression
of PD is associated with degeneration of various regions associated with
emotion.
Psychological factors that can influence the development of depression
are negative thoughts and social isolation (APDA, 2020). Negative thoughts
could be attributed to disease effects. For instance, an individual diagnosed with
PD who has been excluded from family activities, or social gatherings due to their
motor symptoms might be more vulnerable to depression (Saeedian et al., 2014).
The study by Cheng et al., (2008) showed that low social support was associated
with higher levels of depression. Furthermore, the stigma of having tremors, and
slow movement might lead an individual with PD to isolate. The lack of family or
social support, or loss of independence are also important factors that can lead
to depression (Navarta-Sanchez et al., 2016). A review analysis by Reijnders et
al. (2008) found that 35% of PD patients had significant depressive symptoms.
Individuals with PD are more vulnerable to develop depression, anxiety
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disorders, cognitive impairment, and psychosis (Rojo et al., 2003). Depression
can develop at any point in PD, and symptoms can vary. Some studies suggest
that depression symptoms vary based on age. However, in general, studies tend
to be cross-sectional, and they typically have smaller sample sizes. Thus, it is
relevant to examine longitudinal differences in depression rates at different ages
of onset in Parkinson’s disease.
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CHAPTER TWO
AGE AT ONSET OF PARKINSON’S DISEASE

Young-onset Parkinson’s Disease
Young onset Parkinson’s disease (YOPD) or early onset PD (EOPD) is
defined as being diagnosed with PD at any age between 21-40 years old
(Mehanna & Jankovic, 2019). However, recent studies have proposed
inconsistency/variability in these age ranges. According to Rana et al., (2012)
early onset PD begins from ages 21 to 40 or less than 55 years old. However,
other studies have suggested different cutoffs, and proposed three distinct
subgroups: young onset, middle onset, and late onset PD (Mehanna et al., 2014;
Kim et al., 2020). In this study, YOPD included individuals less than 49 years of
age, middle onset included individuals between 50-69 years of age, and late
onset included individuals older than 70 years of age (Mehanna et al., 2014).
YOPD individuals experience earlier motor complications such as
dyskinesia and dystonia (Schrag & Schott, 2006). However, they have also
shown to have less severe motor symptoms compared to older onsets (Post et
al., 2008). YOPD has been associated with slower disease progression, but
longer disease duration (compared to older groups), and less cognitive decline
until later stages (Alves et al., 2005; Schrag et al., 1998). They are also less
disabled compared to the middle and late onset PD groups, and typically have
lower scores on the Hoehn and Yahr rating scale (scale used to measure
severity of Parkinson’s disease symptoms) (Post et al., 2008).
12

One of the most prevalent initial motor symptoms observed in YOPD
patients is tremor. In the study by Mehanna et al., (2014), tremor was an
important initial symptom in more than half (58.3%) of the YOPD group. Gait
complaints and falls (15%), rigidity (21.7%), and bradykinesia (18.3%) were also
important initial symptoms in this group (Mehanna et al., 2014). Seventy percent
of YOPD patients also developed dyskinesia or impairment of voluntary
movement (Mehanna et al., 2014). Regarding cognition, 26.7% of patients in this
group developed dementia (Mehanna et al., 2014). According to Spica et al.,
(2013) YOPD individuals have a lower risk/prevalence of non-motor symptoms
compared to the LOPD group. However, findings on the prevalence of non-motor
symptoms in this PD subgroup are inconsistent.
Depression in Young Onset Parkinson’s Disease
Depression is more frequent among individuals with YOPD (Mehanna et
al., 2014). According to Mehanna et al., (2014) in this sample, depression was
more evident in the YOPD group (48.3% of individuals expressed depressive
symptoms) compared to the MOPD and LOPD (22.1% of individuals in the LOPD
expressed depressive symptoms) groups. In a study conducted by Knipe et al.,
(2011) the YOPD group had worse quality of life and more depressive moods
compared to the LOPD group. In this study, age of onset (YOPD) was a strong
predictor of poorer scores of emotional well-being, even after adjustment of
depression status (Knipe et al., 2011). Another study by Kasten et al., (2012)
showed that the YOPD group had more suicidal ideation compared to the LOPD
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group. Interestingly, the YOPD group displayed higher instances of panic attacks
(24%), and social phobia (19%) compared to the LOPD group (Kasten et al.,
2012). One of the most important risk factors of depression is age of onset,
especially before the age of 55 (Santamaria et al., 1986; as reviewed in Calne et
al., 2008). Disease duration and cognitive impairment were also highly
associated with depression scores in the YOPD group (Starkstein et al., 1989).
The higher occurrence of depression among individuals with YOPD is
likely multifactorial, but at least partially due to psychosocial factors. Employment
is an important factor in YOPD individuals, as it has an effect on self-esteem,
productivity, and financial aid (Schrag & Schott, 2006). Patients with YOPD may
be unemployed or had to retire early due to their disability (Schrag & Schott,
2006). Banks and Lawrence (2006) found that symptom severity and lack of
support in the workplace were main factors of early retirement among patients
with YOPD. They might experience loss of independence when they are at their
peak of productivity which might influence their self-esteem and might lead to
depressive symptoms. Fereshtehnejad et al., (2014) explained how YOPD
patients experience greater psychological features, especially depression,
compared to LOPD patients. Thus, early retirement due to inability to perform
efficiently might lead to or worsen existing depressive symptoms in YOPD
individuals.
Other psychosocial factors such as role expectations significantly
contribute to the development of depression in this group. Schrag et al., (2000)
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suggest that older patients are more compatible/suitable with retirement and the
physical symptoms associated with PD, whereas YOPD individuals struggle to
adjust to these motor symptoms that interfere with their functional activities.
Furthermore, according to the review by van Uem et al., (2016) poor healthrelated quality of life in Parkinson’s disease patients was strongly associated with
social role functioning. In the general social functioning role, PD patients often
experience communication problems (e.g., voice problems) when socializing with
others, which might lead to social withdrawal and isolation (Miller et al., 2006). In
a social setting, PD individuals, especially YOPD, may feel an inability to have
meaningful conversations with others or contribute relevant information.
Social support also plays a major role in the occurrence of depression in
this group. According to Cheng et al., (2008) lower social support is associated
with a higher risk of depression in PD. Family support is also an important
component of well-being and motivation in PD. According to Navarta-Sanchez et
al., (2016) Parkinson’s disease patients who received support from their family
felt more secure and motivated to continue their treatment.
YOPD individuals may also experience more family and marriage
problems (Schrag & Schott, 2006). One of the main negative impacts on couple
relationships is shifting relational roles. For instance, since one partner is unable
to perform their daily activities, the other partner may have more responsibility,
and as a couple, they may also engage in fewer activities together (Habermann,
1996). Some studies have found that reduced relationship satisfaction was
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associated with higher levels of anxiety, and depression, especially in YOPD
individuals (Wielinski et al., 2010; Ricciardi et al., 2015). Lower sexual
satisfaction was also associated with lower marital satisfaction, especially in
YOPD individuals, and those with worse motor symptoms (Bronner et al., 2014).
On the other hand, Karlstedt et al., (2017) found that having a male care partner
increased the positive quality of a relationship.
Stigmatization has also been associated with depression in this group.
Research has shown that young age, and depression were significant predictors
of self-perceived stigma in PD (Salazar et al., 2019). According to Schrag et al.,
(2003), YOPD is associated with greater disease burden, motor complications,
unemployment due to disability, poor quality of life, stigmatization, and
depression. Concerns about stigmatization can influence patients’ perception of
their condition and its treatment, and could lead to avoiding socialization (Verity
et al., 2020). The study by Bhidayasiri et al., (2020) found that YOPD individuals
rated slow movement, performing fine finger movements, stiffness, and muscle
cramping as the most concerning symptoms of PD, which could relate to
problems in social functioning, and stigmatization.
Loss of employment or early retirement, role expectations, low social
support, family and marriage problems, and stigmatization are some of the
factors that have shown to be strongly associated with depression in YOPD.
However, there are other predictors that could also explain the occurrence of
depression in this group.
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Neurobiological Mechanisms in Young Onset Parkinson’s Disease
Some studies have shown brain abnormalities in patients with YOPD.
YOPD patients tend to have greater nigral cell loss than patients with LOPD
(Gibb & Lees, 1988; as reviewed in Schrag & Schott, 2006). Other studies have
found that the YOPD group experiences greater dopamine density loss, thus
partly explaining slower disease progression in this group (de la FuenteFernandez et al., 2011). This group has also shown to have less dopamine
transporter (DAT) density, low levels of cerebrospinal fluid (CSF) lactate, or CSF
t-tau, and low levels of p-tau, which could further explain the early motor
complications observed in this subgroup (Shih et al., 2007; Schirinzi et al., 2020).
Furthermore, in the study by Xuan et al., (2019) there were grey matter
differences observed between the YOPD group and the middle-late onset PD (MLOPD) group. In this study, YOPD patients had reduced grey matter density in
the left putamen, inferior frontal gyrus, and insula (Xuan et al., 2019). Other
studies have found more impairment in the putamen of YOPD compared to
LOPD (Sheng et al., 2016). The putamen is a structure that is part of the basal
ganglia and is involved in learning, motor control, cognitive functioning, and
emotion (Ghandili & Munakomi, 2021). Interestingly, others have found greater
dysfunction in the frontal gyrus, temporal pole, and temporal gyrus in YOPD (Yue
et al., 2020). In summary, YOPD differs from MOPD and LOPD as they display
greater nigral cell loss and dopamine density loss. YOPD individuals also have
reduced grey matter densities in frontal subcortical regions. However, no studies
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have examined if these neuroanatomical differences are associated with agerelated differences in depression.

Middle Onset Parkinson’s Disease
Middle onset PD (MOPD) consists of individuals with disease onset of 5069 years of age (Mehanna et al., 2014). According to Mehanna et al., (2014),
36.1% of individuals in this group developed dementia. Dyskinesia developed in
34.1% of patients in this group (Mehanna et al., 2014). Rigidity (54%) and tremor
(46%) have also shown to be initial motor symptoms in MOPD individuals (Stella
et al., 2008). In a study with MOPD patients, it was shown that depression was a
significant predictor of disability and low quality of life in PD (Menon et al., 2015).
The study conducted by Pellicano et al., (2015) found that body side of onset of
motor symptoms (left versus right) has a slight impact on depressive symptoms
and anxiety. Results from this study suggest that left-sided PD patients may
slightly suffer more depressive symptoms compared to the right-sided PD
patients (Pellicano et al., 2015). It is explained that this is due to the right
hemisphere’s responsibility in processing negative thoughts/emotions.
Depression in Middle Onset Parkinson’s Disease
According to Post et al., (2008) individuals in this intermediate group
experienced more anxiety, and depressive symptoms, and had low perceived
quality of life scores, compared to the older group (LOPD). Depressive symptoms
were reported in 35.1% of this group (Mehanna et al., 2014). Furthermore,
another study by Stella et al., (2008) found that 54% of MOPD patients showed
18

depressive symptoms. Greater UPDRS scores (scale to assess motor symptom
severity) were also highly associated with more depression (Stella et al., 2008).
Other studies have shown similar rates of depression symptoms in MOPD
individuals, typically ranging from 20% to 40% (Rojo et al., 2003; Slaughter et al.,
2001).
Regarding the neural mechanisms of depression, the M-LOPD group had
reduced grey matter density in the left cerebellum posterior lobe, left occipital
lobe, and right supplementary motor area (Xuan et al., 2019). Another study
found decreased grey matter density in the left inferior orbitofrontal gyrus,
bilateral rectal gyrus, and right superior temporal pole of depressed PD patients
compared to non-depressed PD patients (Feldmann et al., 2008). Moreover,
there was a negative correlation between depression severity and gray matter
density of the right medial temporal gyrus, right parahippocampal gyrus, medial
and anterior cingular cortex, and right cerebellum (Feldmann et al., 2008).
Another study found lower activation in the medial prefrontal cortex and left
mediodorsal (MD) of depressed MOPD patients (Cardoso et al., 2009). There
was also increased volume of MD thalamic nuclei in this depressed group, which
could be explained by major input coming from the amygdala, basal ganglia, and
hypothalamus, as they have an important role in emotion (Cardoso et al., 2009).
According to Huang et al., (2015) PD depressed patients showed increased
amygdala metabolism. Regarding white matter loss, the PD depressed group
had more severe white matter loss in the right frontal lobe, including the anterior
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cingulate bundle, and the inferior orbito-frontal region (Petrovic et al., 2012).
These studies have supported the idea that as PD progresses, more brain
regions become affected.

Late Onset Parkinson’s Disease
Late onset PD (LOPD) includes individuals who are diagnosed with
Parkinson’s disease after the age of 70 (Mehanna et al., 2014). This late onset
group shows more motor impairments, and higher rates of disease progression
(Post et al., 2008). In this late onset group tremors were an important initial
symptom (70.1%), followed by gait complaints (22.5%), and bradykinesia
(18.6%) (Mehanna et al., 2014). Depressive symptoms were reported in 22.1% of
patients in this group. According to Mehanna et al., (2014) 34.2% developed
dementia. Dyskinesia developed in 13% of these patients (Mehanna et al., 2014).
Bradykinesia, resting tremor, and postural instability scores were more severe in
older onset subgroups (50-59, 60-69, > 70 years of age) compared to the YOPD
group. Furthermore, in terms of non-motor symptoms, individuals with an older
age at onset had higher impairment in cognitive functioning (Pagano et al., 2016;
Kim et al., 2020).
Depression in Late Onset Parkinson’s Disease
According to Starkstein et al., (1989) depression scores in this group were
highly associated with impairment in activities of daily living (ADL) such as
cooking, bathing, or managing medications. Individuals with typical PD onset
experience a decrease in their ADL abilities, and quality of life compared to
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healthy older adults (Hariz & Forsgren, 2011). In the study conducted by
Starkstein et al., (1990), they found that there was a significant correlation
between depression and physical disability. They also found that longer duration
of PD and greater frequency of history of depression before onset of PD were
highly correlated with depression (Starkstein et al., 1990). However, other studies
have suggested that depression is presented before PD motor symptoms (Taylor
et al., 1986).
Research on age differences in quality of life (QoL) inform the literature on
depression in YOPD and LOPD. Although QoL can be separate from depression,
several studies have indicated that depression, and other non-motor symptoms,
moderately correlate with QoL (Schrag et al., 2000; Kuopio et al., 2000).
Research has indicated that individuals with Parkinson’s disease have lower
quality of life scores compared to healthy controls. More specifically, there are
differences observed in YOPD and LOPD groups. According to Kasten et al.,
(2012) the YOPD group were most unhappy with their ability to work, whereas
the LOPD had more difficulties with mobility. According to this same study, the
LOPD group were less satisfied with their ability to perform their daily activities,
capacity for work, and felt that physical pain prevented them from doing what
they needed to do compared to the YOPD group (Kasten et al., 2012).
Freezing of gait (FOG) is a common motor symptom in Parkinson’s
disease and is mainly observed in the most advanced stages (Giladi et al., 2001;
as reviewed in Moore et al., 2007). FOG is characterized by the inability to move
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the feet forward and is one of the most impairing symptoms of PD (Heremans et
al., 2013). Since FOG tends to occur at unexpected events, such as social
gatherings, or professional events, it can be very unpleasant or embarrassing for
the individual and can prevent future social interactions possibly leading to
depression. Previous studies have associated FOG with depression, stress, and
anxiety (Giladi et al., 2006). Furthermore, FOG has also been directly associated
with QoL. The study by Moore et al., (2007) found that FOG has an important
impact on QoL in PD patients. More specifically, they found a strong association
between FOG and the QoL dimensions of emotion, cognition, and
communication (Moore et al., 2007). Overall, FOG is a motor complication that is
mostly seen in LOPD and may contribute to depression as it has an impact on an
individual’s social life.
Maladaptive coping strategies are also determinants of depression and
anxiety in PD patients. According to Garlovsky et al., (2016) previous studies
have reported that wishful thinking, emotion-focused, and avoidant coping
strategies were highly related to depression and anxiety. Furthermore, in the
study by Hurt et al., (2011) more emotion-focused coping was related to an
increase in anxiety and depression (as reviewed by Garlovsky et al., 2016).
According to other studies, increased illness identity or knowing more about their
PD symptoms and disease have been associated with increased anxiety and
depression (Evans & Norman, 2009). Although maladaptive coping strategies
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could be developed at any point during PD, and at any age of onset, they could
partly explain depressive symptoms in this late-onset group.
In another study conducted by Kim et al., (2020) the late onset group
showed greater anxiety and depression compared to the middle onset PD group.
More specifically, the LOPD group had more rapid progression of cognitive
decline, anxiety, and depression compared to the MOPD patients (Kim et al.,
2020). Advancing age is a major risk factor of PD, therefore, an increase in
LOPD cases is expected (Mercado et al., 2017).
However, age at onset of PD regarding depression and anxiety has been
inconsistent (Pagano et al., 2016; Mehanna et al., 2014; Schrag et al., 2003;
Spica et al., 2013). Differences in results could be due to study designs and
different cut-off values for different ages at onset.
Neurobiological Mechanisms in Older PD Individuals
At later stages of disease, cortical deposition (e.g., Lewy bodies) play a
major role in the development of neuropsychiatric disorders such as anxiety and
depression (Mendonca et al., 2017). The study conducted by Frisina et al.,
(2009) found that depression in older PD individuals (average age = 82 years
old) was related to neuropathology in the brainstem, more specifically areas
where catecholamine systems (norepinephrine, dopamine) are found.
Depression symptoms may be due to catecholamine dysfunction, as by this
stage many brain regions and systems are already severely affected by PD.
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However, these studies only focused on depression in older PD individuals and
did not discuss how age at onset (e.g., LOPD) was related.
Decreased levels of serotonin in the central nervous system (CNS) have
been significantly associated with depression in Parkinson’s disease (Mayeux et
al., 1984). Interestingly, the study by Myslobodsky et al., (2001) showed that
patients who underwent subthalamic nucleus deep brain stimulation had
increased suicidal rates. Suicidal behavior has been associated with
disturbances in serotonin neuroregulation, and dysfunctions in the hypothalamicpituitary adrenal axis (Kostic et al., 1996; as reviewed in Kostic et al., 2010).
Similarly, these studies focused on older PD individuals and depression, but age
at onset was not considered.
Pagano et al., (2016) describe that later onset of PD is associated with
greater dopaminergic dysfunction on DaTSCAN, reduction of CSF alphasynuclein, and total tau, which could explain that greater accumulation of these
are found in healthy neurons. Furthermore, Matsui et al., (2007) found reduced
white matter integrity in the anterior cingulate cortex of depressed PD patients.
Reduction of FA values indicate histological abnormality (Matsui et al., 2007).
Another study by Huang et al., (2014) found reduced integrity in left uncinate
fasciculus, superior longitudinal fasciculus, anterior thalamic radiation, forceps
minor, and the inferior longitudinal fasciculus in depressed PD patients.
To the best of our knowledge, not many studies have investigated the
neural correlates of depression in LOPD. Many of the current literature focuses
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on depression in PD at any stage or they provide possible explanations of
depression occurrence in older PD groups. Therefore, it is concluded that as
individuals age and as disease progresses, there is severe neurodegeneration
potentially explaining the neuropsychiatric symptoms in PD.

Summary of Literature
Overall, these studies provide preliminary evidence in how depression
severity is dependent on age at onset. Young-onset PD individuals tend to
experience more depression symptoms compared to middle- and late-onset PD.
This is partially due to psychosocial factors such as unemployment, low social
support, stigmatization, and role expectations. Additionally, there may be
neuroanatomical differences that contribute to differences in depression rates.
YOPD tend to experience more compromise in frontal subcortical brain regions,
whereas LOPD show more degeneration in temporal regions. However, studies
examining depression as a function of age have been primarily cross-sectional
and with limited sample sizes (sample sizes range from 34 to 105). Additionally,
we are unaware of any studies examining neural correlates of depression as a
function of age.

Present Study
The proposed thesis seeks to increase our understanding of the
occurrence and neural correlates of depression across the spectrum of young,
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middle, and late onset Parkinson’s disease. The overall hypothesis is that rates
and neural correlates of depression will differ across the age spectrum.
Specific Aims
Aim 1: Investigate the longitudinal occurrence of depression among
individuals newly diagnosed with young (< 49 years old), middle (50-69 years
old), and late onset Parkinson’s disease (> 70 years old).
Hypothesis Aim 1: We predict that the young-onset PD group will
experience higher depression rates compared to the middle-, and late-onset
groups.
Rationale for Hypothesis: Previous studies on PD patients have indicated
that depression is most common among YOPD individuals compared to later
onset groups (Mehanna et al., 2014; Knipe et al., 2011; Kasten et al., 2012).
YOPD individuals are at their peak of productivity, thus are most affected by the
disabling motor and non-motor symptoms of this disease. In contrast with
previous studies that have utilized smaller sample sizes (typically ranging from
eight to forty participants) and cross-sectional studies, this study seeks to
examine longitudinal differences in YOPD, MOPD, and LOPD across the five
years of diagnosis.
Aim 2: Investigate the neural correlates of depression among young,
middle, and late onset PD patients.
Hypothesis Aim 2: Depression will be associated with lower neuronal
density in important frontal subcortical regions of YOPD individuals.
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Rationale for Hypothesis: There have been differences in the biological
mechanisms contributing to depressive symptoms in different PD subgroups
(YOPD, MOPD, LOPD) (Xuan et al., 2019; Feldmann et al., 2008; Huang et al.,
2014). YOPD individuals tend to show greater neuronal reduction in frontal
subcortical areas, whereas later onset groups tend to show more loss in temporal
regions (Yue et al., 2020).
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CHAPTER THREE
METHOD

Participants and Study Design
The current study utilized data from the Parkinson’s Progression Marker’s
Initiative (PPMI) database. The PPMI is a longitudinal multisite observational
study to measure and identify biomarkers of Parkinson’s disease progression.
Participants provided written informed consent, and the institutional review board
approved this study. There were approximately 487 participants newly diagnosed
with Parkinson’s disease who completed a questionnaire of depression at each
annual follow up (five annual follow-ups). Aim two utilized a subsample of
approximately 133 individuals (only 133 individuals had neuroimaging data) that
underwent head MRI at baseline and first annual follow-up.
Age Groups
Age groups will be classified based on past studies. YOPD will include
individuals under the age of 49 years old, MOPD will include individuals between
the ages of 50 and 69 years old, and LOPD will include individuals over the age
of 70.
Measures
Depression. The Geriatric Depression Scale, short form (GDS) was used
to measure depressive symptoms in PD patients. The GDS is a self-report
measure of depression in older adults and has shown to be a reliable measure in
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PD, as it measures depression across a range of PD severity (Schrag et al.,
2007). Unlike other questionnaires, the GDS primarily assesses the emotional or
behavioral symptoms of depression, as opposed to somatic symptoms of
depression that may be confounded by the motor symptoms experienced by
individuals with PD. Some questions included in the GDS were, “Have you
dropped many of your activities and interests?” and “Do you feel that your
situation is hopeless?” Participants were administered the GDS at baseline, and
at each annual follow-up.
Severity of Motor Symptoms. The Unified Parkinson’s Disease Rating
Scale (UPDRS) assessed severity of motor symptoms (Goetz et al., 2008). More
specifically, part III (Motor Examination) of the scale measures motor symptom
severity, with higher scores indicating greater severity of motor symptoms. The
motor examination section assesses speech, facial expression, tremor, rigidity,
posture, gait, and bradykinesia (Goetz et al., 2008).
Levodopa Equivalent Dose (LED). Since some patients are in certain
brands of dopaminergic medication, whereas others are in other brands, and
these differences might be meaningful, conversion factors were utilized to
produce a total daily levodopa equivalent dose (LED).
MRI Analyses
Participants underwent neuroimaging at baseline and at a one-year followup. MRI parameters can be found at http://www.ppmi-info.org/wpcontent/uploads/2010/07/Imaging-Manual.pdf. Briefly, parameters were repetition
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time 5–11 ms; echo time 2–6 ms; slice thickness 1–1.5 mm; inter slice gap 0 mm;
voxel size 1*1*1.2 mm; matrix 256 * minimum 160. MR images were visually
inspected, and quality controlled before further processing. FreeSurfer
(http://surfer.nmr.mgh.harvard.edu) was used to reconstruct and sement T1weighted images. This involved standard FreeSurfer preprocessing procedures,
which resulted in automated parcellation of cortical surfaces and subcortical
structures defined by the Harvard-Oxford cortical and subcortical atlases
(Desikan et al., 2006; Fischl et al., 2004) and extraction of regional volume and
cortical thickness (Fischl and Dale, 2000). The regions analyzed are listed in
Table 1.
Statistical Analyses
Aim 1. We investigated the longitudinal occurrence of depression among
individuals newly diagnosed with young, middle, and late onset Parkinson’s
disease. Regarding descriptive statistics, the average GDS score for each age
group (young, middle, and late onset PD) was reported at each annual
assessment. Additionally, the percent of individuals experiencing significant
clinical symptoms of depression (GDS ≥ 5) for each age group was reported.
Multilevel modeling (MLM) examined longitudinal group differences in
depression severity. GDS total scores were entered as the dependent variable.
Independent variables included gender, education, UPDRS scores, age group,
occasion, and an age group by occasion interaction. The interaction term
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examined if certain age groups were more/less likely to experience longitudinal
changes in depression.
Aim 2. Investigated the neural correlates of depression among young,
middle, and late onset PD patients. MLM examined the association between
depression and structural brain markers among age groups. GDS total scores
were entered as the dependent variable. Independent variables included gender,
education, UPDRS scores, age group, occasion, MRI region volume and their
associated interaction terms. Models were repeated for each MRI region (a total
of 53 regions).
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CHAPTER FOUR
RESULTS

From the 487 participants, the majority identified as male (65.1%), and
Caucasian (94.9%). In terms of age at onset, the majority were in the MOPD
group (66.5%). Other demographic characteristics are summarized in Table 2.
Our first aim sought to investigate the longitudinal occurrence of depression
among individuals newly diagnosed with young, middle, and late onset
Parkinson’s disease. In the model with no medications (anti-depressants and
Levodopa), there was a significant group X occasion interaction effect.
Specifically, the LOPD group indicated higher depression scores overtime when
compared to the MOPD group (see Table 3). There were no longitudinal
differences in depression between the YOPD group when compared to the LOPD
group (see Table 3). There is no main effect of group; meaning the YOPD and
MOPD groups did not differ from the LOPD group in depression scores (see
Table 3). Regarding motor symptoms, higher severity of motor symptoms was
indicative of higher depression scores (see Table 3). Furthermore, there was a
significant effect of occasion, meaning individuals became more depressed the
longer they have been on the study. Gender was not a significant predictor (see
Table 3). Overall, our results showed that the average score for the GDS-15
short form was 2.46. Scores that are greater or equal than 5 suggest depression.
This suggests that our group was generally non-depressed. In this model, we are
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explaining 6% of the variance between participants, and 20.7% within
participants.
In the model with medications (anti-depressants and Levodopa), results
indicated the group X occasion interaction effects were no longer significant.
Individuals in the LOPD group did not significantly differ in depression severity
over time when compared to the MOPD, neither does the LOPD group when
compared to the YOPD group after controlling for Levodopa and use of antidepressant medications (see Table 4). The main effect of group was not
significant either (see Table 4). Gender was not significant. The use of Levodopa
was not significant; however, more severe depressive scores were predicted by
antidepressant use, and more severe motor symptoms (see Table 4).
Our second aim sought to investigate the neural correlates of depression
among young, middle, and late onset PD patients. Results for our second aim
demonstrated a negative association between brain volume in the frontal medial
cortex and depression severity. More specifically smaller volumes in the frontal
medial cortex were associated with more depression but only in the MOPD group
(see Table 5). On the other hand, there was a positive trend between brain
volume and depression severity in the YOPD and LOPD groups (see Figure 1).
Other brain regions were not significant after adjusting for multiple comparisons
(p > .05).
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CHAPTER FIVE
DISCUSSION
Our results indicated that the LOPD group displayed more severe
depression than the MOPD group overtime; however, there were no longitudinal
differences in depression severity between the LOPD and YOPD groups.
Furthermore, smaller volumes in the frontal medial cortex were associated with
higher depression severity, but only in the MOPD group.
Past studies have found significant differences between depression and
age at onset in PD individuals. Thus, we hypothesized that individuals with
YOPD would experience higher depression severity than individuals with LOPD.
However, our findings showed that there were no differences in depression
between these groups. These inconsistencies might be explained by different
research study designs. Other studies have been cross-sectional and have not
examined these differences over time (Schrag et al., 2003; Mehanna et al.,
2014). Furthermore, our study had relatively less individuals in the YOPD
(13.3%) and LOPD (66.5%) groups compared to the MOPD sample (66.5%).
Previous studies that have found differences in depression between YOPD
individuals, and LOPD tend to have more individuals in these groups. For
instance, the study by Knipe et al., (2011) had 90 individuals in the YOPD group,
and 336 in the LOPD, whereas in our study, we only had 65 individuals in the
YOPD group and 98 in the LOPD group. Thus, given that larger sample sizes
have an impact on significance, perhaps having more individuals in these groups
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could have led to significant differences in depression. Furthermore, our sample
was largely non-depressed given they had an average score of 2.46 on the GDS
scale. A score of less than or equal to 5 indicates minimal depressive symptoms,
whereas scores ≥ 5 indicate mild or severe depression (Yesavage et al., 1983).
Having a non-depressed sample gave us a restricted range or less variability of
depression severity across these groups.
There have been other studies that have found no differences in
depression between YOPD and typical-onset PD (Kim et al., 2020). The study by
Kim et al., (2020) found differences in depression between the YOPD group and
MOPD group, but only at baseline; they did not differ overtime. They suggest that
these baseline differences may not be disease-specific but instead related to
psychosocial factors such as stigma and loss of normal functioning (Kim et al.,
2020). Other studies also have not found a relationship between depression and
age of PD onset (Riedel et al., 2010; Borek et al., 2006).
Regarding differences between the LOPD and MOPD groups, LOPD
individuals became more depressed overtime compared to MOPD individuals.
This finding may partially support our hypothesis that age is associated with
depression. Although it was in the alternate direction that we anticipated, there is
a precedent for age being a risk factor for depression. Raket et al., (2022) found
that in PD, higher age at onset was associated with more severe course of
disease. More specifically, they found that later onset of PD was related to more
non-motor symptoms, including depression, and the appearance of more
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symptoms over time (Raket et al., 2022). Furthermore, later onset was also
related to worse health-related quality of life scores (Raket et al., 2022). Quality
of life has been associated with depression in PD. Schrag et al., (2000) found
that individuals with higher depression levels had worse quality of life scores.
Other studies have further supported that depression and worse quality of life in
PD are strongly related (Findley & Global Parkinson’s Disease Steering
Committee, 1999).
Disability and higher motor impairments also have been related to
depression in old onset PD. Post et al., (2008) found that older onset PD groups
have more rates of disease progression and motor impairment compared to
younger onsets. Furthermore, increasing age at onset was associated with
higher levels of disability, and lower perceived quality of life (Post et al., 2008).
Disability leads to an impairment in activities of daily living which commonly
include bathing, eating, and taking medications. Furthermore, a decrease in
activities of daily living have been associated with worse perceived quality of life
(Hariz & Forsgren, 2011). Therefore, higher motor impairments, disability, and
perceived quality of life in late-onset PD group lead to more depression
compared to younger onsets.
Further supporting our findings, the study by Kim et al., (2020) found that
LOPD individuals had a faster progression of cognitive impairment, depression,
and anxiety compared to the MOPD group. In this study, the LOPD group also
had a faster progression of motor severity (Kim et al., 2020). It is suggested that
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the aging process and its contribution to the neurodegeneration in PD may be
explaining depression in this LOPD group (Hindle, 2010).
Regarding the effect of medication, findings show that when medications
(anti-depressants) are added in the model, there are no differences observed
between these groups. An explanation for this could be the positive association
between anti-depressant use and depression. More specifically, higher use of
anti-depressants is associated with more depressive symptoms. This may not be
surprising considering that individuals without depression have no (or at least
minimal) clinical reason to be taking anti-depressants. When anti-depressants
are added in the model it may be reducing systematic variance in depression that
we seek to address in this study.
For our second aim, we found smaller volumes in the frontal medial cortex
were associated with more severe depression in our MOPD group (see Figure 1).
The frontal medial cortex plays an important role in decision-making and
guidance of emotional related behavior (Ongur & Price, 2000). Past studies have
shown that functional and structural abnormalities in the frontal medial cortex
have been observed in patients with major depressive disorder (Kanner, 2004;
Davidson et al., 2003). Thus, consistent with previous research, it is not
surprising that lower volumes in this region are associated with more depression.
Interestingly, we did not observe similar findings in the YOPD and LOPD groups.
This could be explained by depression being influenced by psychosocial stress
(e.g., early retirement) experienced by the YOPD group rather than neurologic
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effects. In regard to the neural basis of depression in LOPD, we did not find an
association between any brain region and depression in this group. A reasonable
explanation for this is differences in techniques/scanners. Previous studies have
found heterogenous findings regarding the neurobiology of depression in
Parkinson’s disease and older adults (Kano et al., 2011). For example, the study
by Remy et al., (2005) suggested that depression may be associated with the
loss of dopamine and noradrenaline in the nervous system. Therefore, since PD
is primarily defined by the loss of dopaminergic neurons, it is not surprising that
depression is also present. Furthermore, other studies have found lower cerebral
spinal fluid levels of homovanillic acid (a catecholamine metabolite associated
with dopamine levels) in depressed individuals (Roy et al., 1985). The study by
Pagano et al., (2016) used DaTSCAN imaging, which shows loss of
dopaminergic neurons, and found group differences in depression. On the other
hand, the study by Huang (2014) used diffusion tensor imaging and found
reductions in certain brain regions of depressed PD patients. Therefore,
differences in techniques/scanners could lead to inconsistent findings.
Some of the limitations in our study were that participants were
predominantly Caucasian males; potentially limiting generalizability to other
diverse populations. Another limitation was that there was an unequal number of
participants in each age group. There were more participants in the MOPD group
than the YOPD and LOPD groups. Other studies that have found significant
differences between age of onset and depression in PD have had slightly more
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participants in the YOPD and LOPD groups (Knipe et al., 2011). et al., 2003).
Furthermore, our sample is highly functioning/largely non-depressed which gave
us a restricted range.
Future studies could expand more on these findings by using a more
diverse sample, and fairly similar number of individuals in each age-at-onset
group. Overall, our findings show that there are significant group differences in
depression overtime between the LOPD and MOPD groups, and that the frontal
medial cortex plays an important role in depression severity in our MOPD group.
Due to the amount of limited research in depression in Parkinson’s disease this
study further expands on the literature by demonstrating significant differences in
depression (and structural differences) overtime between groups. Given that the
LOPD group becomes more depressed overtime compared to a younger onset
group, better treatments and drug therapies could be developed to treat
depression.
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APPENDIX A
TABLE 1. CORTICAL AND SUBCORTOCAL REGIONS ANALYZED
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Table 1
Cortical and Subcortical Regions Analyzed
Cortical
Frontal Pole

Temporal Occipital Middle
Temporal Gyrus

Inferior Lateral Occipital
Cortex

Anterior Inferior Temporal
Gyrus

Intracalcerine Cortex

Insula cortex
Supramarginal Frontal Gyrus

Lingual Gyrus
Anterior Fusiform Gyrus
Posterior Fusiform Gyrus

Supplementary Motor Cortex
Middle Frontal Gyrus

Posterior Inferior Temporal
Gyrus

Subcallosal Cortex

Temporal Occipital Fusiform
Gyrus

Paracingulate Cortex

Occipital Fusiform Gyrus

Anterior Cingulate Gyrus

Frontal Operculum Cortex

Posterior Cingulate Gyrus

Central Operculum Cortex

Precuneus Cortex

Parietal Operculum Cortex

Cuneal Cortex

Planum Temporale

Frontal Orbital Cortex

Heschls Gyrus

Anterior Parahippocampal
Gyrus

Supracalcerine Cortex

Pars Triangularis
Pars Opercularis

Temporal Occipital Inferior
Temporal Gyrus

Precentral Gyrus

Posterior Central Gyrus

Temporal Pole

Superior Parietal Lobule

Anterior Superior Temporal
Gyrus

Anterior Supramarginal Gyrus

Posterior Superior Temporal
Gyrus

Posterior Supramarginal
Gyrus
Angular Gyrus

Anterior Middle Temporal
Gyrus
Posterior Middle Temporal
Gyrus

Superior Lateral Occipital
Cortex

Occipital Pole
Posterior Parahippocampal
Gyrus

Frontal Medial Cortex
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Subcortical
Brain stem

Bilateral Amygdala

Bilateral Caudate

Bilateral Cerebral White
Matter

Bilateral Hippocampus

Bilateral Cerebral Cortex
Bilateral Accumbens
Bilateral Pallidum

Bilateral Lateral Ventricle
Bilateral Thalamus
White Matter

Cerebrospinal Fluid
Bilateral Putamen

Grey Matter
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APPENDIX B
TABLE 2. BASELINE CHARACTERISTICS
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Table 2
Baseline characteristics
Mean

SD

IQR

% YOPD

13.3%

--

---

% MOPD

66.5%

% LOPD

20.1%

Education

15.48

3.118

5-26

% Male

65.1%

--

--

% Caucasian

94.9%

--

--

Motor Severity

20.03

9.195

2-51

GDS

2.46

2.647

0-15

Note. N = 487. SD = Standard deviation; IQR = Inter-Quartile Range; GDS = Geriatric
Depression Scale scores.
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APPENDIX C
TABLE 3. MLM PREDICTORS OF DEPRESSION (MODEL WITHOUT
MEDICATIONS)
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Table 3
MLM: Predictors of Depression (model without medications) (N = 487).
Estimate

SE

Sig.

YOPD vs. LOPD

-.005800

.136602

.966

MOPD vs. LOPD

-.105574

.099363

.289

LOPD vs. YOPD X Occasion

-.115182

.064316

.074

LOPD vs. MOPD X Occasion

-.127861

.047551

.007

Gender

.050458

.080372

.530

Occasion

.116297

.042612

.007

Motor severity

.173693

.029164

<.001

Model Fit
*Δ -2LL
*Δ AIC
*Δ BIC
Between-Person Pseudo r2
Within-Person Pseudo r2

187
169
117
0.062
0.207

<.001
<.001
<.001

SE = Standard error; Sig. = Significance (significant p values shown in bold). LL = Log
Likelihood; AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion.
Gender was coded as: 0 = male, 1 = female. *Change in model indices relative to a null
model with no predictors.
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APPENDIX D
TABLE 4. PREDICTORS OF DEPRESSION (MODEL WITH MEDICATIONS)
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Table 4
MLM: Predictors of Depression (model with medications) (N = 487).
Estimate

SE

Sig.

Age YOPD vs LOPD

-.198755

.150982

.189

Age MOPD vs LOPD

-.199472

.108721

.067

LOPD vs YOPD x Occasion

-.015220

.098364

.877

LOPD vs MOPD x Occasion

-.061282

.073368

.404

Gender

.027321

.090235

.303

Occasion

.062650

.065543

.340

Motor severity

.153299

.033916

<.001

Anti-depressants

-.615316

.085773

<.001

Levodopa

.000064

.000052

.219

Model Fit
*Δ -2LL
*Δ AIC
*Δ BIC
Between-Person Pseudo r2
Within-Person Pseudo r2

2120
2098
2041
0.088
0.239

<.001
<.001
<.001

SE = Standard error; Sig. = Significance (significant p values shown in bold). LL = Log
Likelihood; AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion.
Gender was coded as: 0 = male, 1 = female.
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APPENDIX E
TABLE 5. NEURAL CORRELATES OF DEPRESSION
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Table 5
Neural Correlates of Depression (N = 487).
Estimate

SE

Sig.

YOPD X Frontal Medial Ctx.

.055760

.171358

.909

MOPD X Frontal Medial Ctx.

-.384810

.137498

.038

Note. SE = Standard error; Sig. = Significance
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APPENDIX F
FIGURE 1. NEURAL CORRELATES OF DEPRESSION
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Figure 1
Neural Correlates of Depression in YOPD, MOPD, and LOPD

Note. Each regression line represents our groups. The MOPD group displayed
higher scores in depression severity which were significantly associated with
lower frontal medial cortex volumes.
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